TempraMed signs LOI with CPO Greece
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The announcement is a modest positive for TempraMed, signaling continued international expansion and potential revenue growth, though the non-binding nature and lack of finalized terms limit immediate impact. For CPO Group, the agreement could enhance its product portfolio in the Greek healthcare market, but the financial impact is likely minimal in the short term.
TempraMed Technologies, a medical-technology company specializing in temperature-controlled medication storage, announced on September 1, 2026 that it has signed a non-binding letter of intent (LOI) dated July 30, 2026 with CPO Greece, a division of CPO Group, for the exclusive distribution of its VIVI Cap and VIVI Epi products in Greece. The proposed exclusivity is subject to the execution of a definitive distribution agreement and CPO's compliance with minimum annual purchase obligations, including a requirement to increase combined purchases by at least 20% year over year. Transfer pricing and first-year minimum unit commitments are yet to be finalized. This LOI is part of TempraMed's strategy to expand internationally through local distribution partners, having added or renewed agreements in markets including Panama, Mexico, South Korea, Turkey, Saudi Arabia, Israel, Kuwait, Brazil, and the Benelux region since Q4 2025. The agreement, if finalized, would establish Greece as an additional European market for TempraMed's products. The LOI is non-binding and there is no assurance that a definitive agreement will be reached.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard